Table 1 Demographics and clinical characteristics of patients in the primary and validation cohort
From: Development and validation of a risk prediction score for patients with nasopharyngeal carcinoma
Characteristic | Primary cohort | Validation cohort |
|---|---|---|
n = (363) No. (%) or Mean ± sd | n = (156) No. (%) or Mean ± sd | |
Gender | ||
Male | 209 (57.57%) | 92 (58.97%) |
Female | 154 (42.43%) | 64 (41.03%) |
Age (years) | 46.05 ± 10.87 | 46.87 ± 11.58 |
Smoking | ||
No | 277 (76.31%) | 123 (78.85%) |
Yes | 86 (23.69%) | 33 (21.15%) |
Family history | ||
Yes | 87 (23.97%) | 50 (32.05%) |
No | 276 (76.03%) | 106 (77.95%) |
BMI (kg/m2) | 23.17 ± 6.74 | 22.96 ± 3.37 |
TNM stagea | ||
I | 11 (3.03%) | 6 (3.85%) |
II | 47 (12.95%) | 22 (14.10%) |
III | 179 (49.31%) | 69 (44.23%) |
IV | 126 (34.71%) | 59 (37.82%) |
Treatment | ||
Radiotherapy | 300 (82.64%) | 129 (82.69%) |
Chemotherapy | 63 (17.36%) | 27 (17.31%) |
WBC (109/L) | 7.03 ± 3.33 | 7.04 ± 3.32 |
Neutrophils (109/L) | 4.55 ± 2.87 | 4.35 ± 2.25 |
Lymphocyte (109/L) | 1.71 ± 0.73 | 1.65 ± 0.81 |
Monocyte (109/L) | 0.47 ± 0.24 | 0.43 ± 1.20 |
Platelet (109/L) | 225.02 ± 69.18 | 214 ± 67.46 |
HGB (g/L) | 136.63 ± 15.84 | 137.38 ± 15.62 |
NLR | 3.33 ± 3.82 | 3.34 ± 2.87 |
dNLR | 2.30 ± 2.28 | 2.48 ± 4.13 |
LMR | 4.67 ± 4.59 | 4.58 ± 3.49 |
PLR | 157.39 ± 89.41 | 156.89 ± 86.88 |
SII | 757.39 ± 822.18 | 719.40 ± 692.30 |
TP (g/L) | 73.28 ± 5.89 | 75.56 ± 5.24 |
ALB (g/L) | 43.40 ± 3.29 | 43.17 ± 3.23 |
GLOB (g/L) | 29.88 ± 4.67 | 29.39 ± 4.50 |
AGR | 1.49 ± 0.24 | 1.50 ± 0.26 |
CRP (mg/L) | 4.69 ± 9.93 | 5.42 ± 9.81 |
CAR | 0.11 ± 0.26 | 0.13 ± 0.27 |
APOA (g/L) | 1.31 ± 0.25 | 1.32 ± 0.27 |
APOB (g/L) | 0.99 ± 0.24 | 0.98 ± 0.25 |
ABR | 1.40 ± 0.42 | 1.42 ± 0.47 |
LDH (U/L) | 174.47 ± 54.26 | 176.76 ± 119.25 |
HDL (U/L) | 1.23 ± 0.31 | 1.221 ± 0.31 |
EBV DNA (copy/mL) | ||
< 103 | 167 (48.8%) | 72 (40.5%) |
103–9999 | 77 (20.8%) | 31 (20.8%) |
104–99,999 | 66 (16.8%) | 31 (22.5%) |
105–999,999 | 36 (8.4%) | 10 (9.8%) |
≥ 106 | 17 (5.2%) | 12 (6.4%) |
VCA-IgA | ||
< 1:80 | 59 (17.1%) | 28 (16.2%) |
1:80–1:320 | 221 (60.1%) | 93 (61.3%) |
≥ 1:640 | 83 (22.8%) | 35 (22.5%) |
EA-IgA | ||
< 1:10 | 111 (30.6%) | 51 (28.3%) |
1:10–1:20 | 121 (33.3%) | 49 (34.7%) |
≥ 1:40 | 131 (36.1%) | 56 (37.0%) |
PNI | 51.94 ± 5.09 | 51.4 ± 5.17 |
PI | ||
0 | 297 (81.82%) | 119 (76.28%) |
1 | 59 (16.25%) | 35 (22.44%) |
2 | 7 (1.93%) | 2 (1.28%) |